Artificial Antigen-Presenting Cells for Use in Adoptive Immunotherapy
- 1 July 2010
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 16 (4) , 374-381
Abstract
The observation that T cells can recognize and specifically eliminate cancer cells has spurred interest in the development of efficient methods to generate large numbers of T cells with specificity for tumor antigens that can be harnessed for use in cancer therapy. Recent studies have demonstrated that during encounter with tumor antigen, the signals delivered to T cells by professional antigen-presenting cells can affect T-cell programming and their subsequent therapeutic efficacy. This has stimulated efforts to develop artificial antigen-presenting cells that allow optimal control over the signals provided to T cells. In this review, we will discuss the advantages and disadvantages of cellular and acellular artificial antigen-presenting cell systems and their use in T-cell adoptive immunotherapy for cancer.Keywords
This publication has 78 references indexed in Scilit:
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in HumansTransplantation and Cellular Therapy, 2010
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor EradicationMolecular Therapy, 2010
- Overview of a HLA-Ig based “Lego-like system” for T cell monitoring, modulation and expansionImmunologic Research, 2010
- A Distinct Subset of Self-Renewing Human Memory CD8+ T Cells Survives Cytotoxic ChemotherapyImmunity, 2009
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cellsNature Medicine, 2009
- Use of tumour-responsive T cells as cancer treatmentThe Lancet, 2009
- In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC)Cancer Immunology, Immunotherapy, 2008
- Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccinesCancer Immunology, Immunotherapy, 2008
- Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania majorNature Medicine, 2007
- Direct stimulation of T lymphocytes by immunosomes: Virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory moleculesProceedings of the National Academy of Sciences, 2006